Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Haleon (Suzhou) Pharmaceutical Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This activity is distributed across 1 distinct examiner and 1 distinct art unit, indicating a specialized and focused prosecution phase. The presence of 1 pending office action within a single art unit suggests that the company is pursuing a specific pharmaceutical or biotechnological innovation rather than a broad array of diverse technologies. This concentration allows for a targeted approach to claim amendments and arguments.
The busiest examiner for this portfolio is WERTZ, ASHLEE ELIZABETH, who is managing 1 busiest examiner pending action. Because 1 distinct examiner is handling the entirety of the pending workload, the prosecution strategy is inherently centralized. Practitioners can focus their efforts on the specific requirements and historical preferences of this 1 examiner to resolve the 1 pending office action. This streamlined interaction reduces the complexity often found in larger portfolios where various examiners might issue different requirements across various applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WERTZ, ASHLEE ELIZABETH | 1 | 49.1% | +40.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291716 | IMPROVED MANUFACTURING PROCESS | WERTZ, ASHLEE ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291716 | IMPROVED MANUFACTURING PROCESS | WERTZ, ASHLEE ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291716 | IMPROVED MANUFACTURING PROCESS | WERTZ, ASHLEE ELIZABETH | 1612 | §103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHaleon (Suzhou) Pharmaceutical Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Ashlee Elizabeth Wertz has the most, with 1 of Haleon (Suzhou) Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.